Enovis vs Insulet
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Enovis and Insulet side by side, using each one’s latest annual report. Here is what stands out:
- Insulet is the larger business, with $2.7B of revenue in fiscal 2025 against $2.2B for Enovis.
- Insulet grew revenue faster (30.7%, against 6.7%).
- Insulet kept more of each dollar of sales as operating profit (17.5% operating margin, against −50.0%).
- Insulet turned more of its sales into free cash flow (14.0% FCF margin, against 0.9%).
- Insulet earned a higher return on the capital invested in it (20.4%, against −26.9%).
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
Enovis
ENOV
0/11
Insulet
PODD
11/11
Revenue growth5-year growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | ENOV FY25 | PODD FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.2B | $10.4B |
| Revenue | $2.2B | $2.7B |
| Free cash flow | $19.9M | $378M |
| Net income | −$1.2B | $247M |
| Growth | ||
| Revenue growth | 6.7% | 30.7% |
| 5-year growth | 14.9% | 24.5% |
| Share count change | 3.2% | −2.7% |
| Profitability | ||
| Gross margin | 59.8% | 71.6% |
| Operating margin | −50.0% | 17.5% |
| Net margin | −52.7% | 9.1% |
| FCF margin | 0.9% | 14.0% |
| Return on capital | −26.9% | 20.4% |
| Return on equity | −58.5% | 18.1% |
| Balance sheet | ||
| Net debt | $1.3B | $233M |
| Net debt / EBITDA | 5.7x | 0.4x |
| Dividends and buybacks | $3.5M | $59.6M |
| Valuation & quality | ||
| P/E | — | 28.0x |
| Piotroski F-score | 4 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.